A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab/pembrolizumab (Primary) ; MK-4830 (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab/Quavonlimab (Primary) ; Vibostolimab+pembrolizumab (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

27 Jun 2024 Status changed from recruiting to active, no longer recruiting.
08 Apr 2024 Planned End Date changed from 28 Oct 2025 to 18 Nov 2025.
08 Apr 2024 Planned primary completion date changed from 28 Sep 2025 to 20 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight